Clinical Management and Key Considerations to Target Optimal Treatment of Inflammatory Bowel Disease

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2022, to August 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Bristol-Myers Squibb

Description:
Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1.6 million people in the United States. This lifelong, systemic autoimmune illness often strikes patients at a young age and must be managed across a lifetime. According to the Crohn’s and Colitis Foundation of America, there are as many as 70,000 new cases diagnosed in a year. The diagnosis of IBD is most commonly based on imaging to assess the portions of the small bowel that are inaccessible to optical endoscopic visualization, which may also include a combination of endoscopy and histopathology. Imaging plays a critical role in the initial diagnosis and ongoing evaluation of IBD patients.

Upon completion of this activity, participants will be able to:

  • Review guidelines on management and treatment of inflammatory bowel disease (IBD)

  • Describe new diagnostic methods for IBD patients

  • Analyze recent clinical trial data regarding the next generation of therapies, including S1P therapies and JAK inhibitors, in IBD management

  • Explore the current and emerging therapies by looking at their safety, efficacy, and mechanisms of action, with a close look at the impact of biosimilars

  • Identify treatment challenges and adverse events in patients with IBD

  • Discuss the role of the multidisciplinary team in improving patient outcomes for IBD

     

Faculty: Francis A. Farraye, MD, MSc
Director, Inflammatory Bowel Disease Center
Professor of Medicine, Department of Gastroenterology and Hepatology
Mayo Clinic

Disclosure:

(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Farraye has served on an advisory board for Arena, BMS, Briantree Labs, GSK, Iterative Scopes, Janssen, Pfizer, and Sebela. He has served on the DSMB for Bacainn Therapeutics, Lilly, and Theravance. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Bristol-Myers Squibb


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue